公开(公告)号：US20110086367A1

公开(公告)日：2011-04-14

申请号：US12294987

申请日：2007-04-03

申请人： Michael Probst-Kepper ,  Frank Ocklenburg ,  Darius Moharregh-Khiabani ,  Robert Geffers

发明人： Michael Probst-Kepper ,  Frank Ocklenburg ,  Darius Moharregh-Khiabani ,  Robert Geffers

IPC分类号： C07K14/47 ,  C12N5/0783 ,  C12N15/86 ,  C12Q1/04 ,  G01N33/566

CPC分类号： A61K35/17 ,  A61K38/179

摘要： The present invention uses the potency and efficacy of human glycoprotein-A repetitions predominant protein (GARP), the gene of which is located on chromosome 11q13-11q14 in the reprogramming of antigen-specific effector T-helper cells, which are CD4+, towards a regulatory pheno type of pre-determined suppressor activity. In contrast to the known regulatory protein Foxp3 that only induces an incomplete regulatory phenotype without suppressor function, GARP is more efficient in inducing suppressor activity. Further, the use of GARP in the manufacture of pharmaceutical compositions is provided, allowing the production of antigen-specific Treg-cells, having a predetermined suppressor activity for a specific antigen.

摘要翻译： 本发明使用人类糖蛋白-A重复主导蛋白（GARP）的功效和功效，其基因位于染色体11q13-11q14上，将抗原特异性效应子T辅助细胞重新编程为CD4 + 调节性类型的预定抑制活性。 与仅仅诱导不具有抑制功能的不完全调节表型的已知调节蛋白Foxp3相反，GARP在诱导抑制活性方面更有效。 此外，提供了在制备药物组合物中使用GARP，允许产生对具体抗原具有预定抑制活性的抗原特异性Treg细胞。